Unlearn.AI Announces Series A Extension with New Investment from Epic Ventures, Alumni Ventures Group, and Global Pharma Company Eisai
Summary
SAN FRANCISCO--(BUSINESS WIRE)--Unlearn®, developer of the first machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, today announced that Eisai, a leading global research and development-based pharmaceutical company, has joined the company’s world-class syndicate of investors as part of its Series A extension along with Epic Ventures and Alumni Ventures Group. “Unlearn has proven how generative AI-models trained on clinical data can be successfully utilized to create Digital Twins of patients for complex populations such as Alzheimer’s Disease. We believe that the Unlearn technology and its Intelligent Control Arms have the potential to solve the enrollment challenges, timeline delays, and high failure rates that too often burden clinical trials,” said Shun Asami, Ph.D., Senior Director, Eisai Innovation. Study sponsors can incorporate a cohort of Digital Twins matched to all of the patients in a given trial to populate Intelligent Control Arms. Unlearn is working with biopharmaceutical and medical device companies as well as regulators to ensure its methods meet the highest scientific and regulatory standards.